ArticleJournal for immunotherapy of cancer2022
Cancer stem-like cells evade CD8
Article in Journal for immunotherapy of cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 37 citations in OpenAlex.
- Loop of N2-polarized neutrophils and exhausted CD8 + T cells induces immunotherapy resistance in NSCLC.Molecular and cellular biochemistry · 2026Article
- The Proximity of PD-1Cancers · 2026Article
- Single-cell analysis identifies a stemness-associated tumor cell subpopulation and develops a prognostic scoring model in esophageal squamous cell carcinoma.Translational oncology · 2026Article
- Mechanisms of T cell-mediated antitumor immunity within tertiary lymphoid structures.Frontiers in immunology · 2026Review
- Hypoxia-Induced TGFBI Promotes Bladder Cancer Progression by Creating a Stemness Regulation Loop through Stabilizing the Disulfide Bonds of GDF15.Research (Washington, D.C.) · 2026Article
- Wnt3a-expressing cancer stem cells impair CD8Oncoimmunology · 2025Article
- Tissue-Resident Memory T Cells: Pioneering New Avenues in Cancer Immunotherapy.Cancer medicine · 2025Review
- Multifaceted functions of tissue-resident memory T cells in tumorigenesis and cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2025Review
- CD44 on cancer stem cell is a potential immunological and prognostic pan-cancer biomarker.Cancer cell international · 2025Article
- New insights on anti-tumor immunity of CD8Journal of translational medicine · 2025Review
- YAP/TEAD involvement in resistance to paclitaxel chemotherapy in lung cancer.Molecular and cellular biochemistry · 2025Article
- Targeting CSC-immune cell crosstalk to overcome chemoresistance and enhance immunotherapy efficacy.Frontiers in immunology · 2025Review
- Crosstalk between cancer stem cells and myeloid-derived suppressor cells: implications for tumor progression and immunotherapy.Frontiers in immunology · 2025Review
- Breaking Immunosuppression to Enhance Cancer Stem Cell-Targeted Immunotherapy.International journal of biological sciences · 2025Review
- A hybrid epithelial-mesenchymal transition program enables basal epithelial cells to bypass stress-induced stasis and contributes to a metaplastic breast cancer progenitor state.Breast cancer research : BCR · 2024Article
- An adaptive Epithelial-Mesenchymal Transition Program Enables Basal Epithelial Cells to Bypass Stress-Induced Stasis and Contributes to Metaplastic Breast Cancer Progenitor State.Research square · 2024Article
- Phenotypic and spatial heterogeneity of CD8Molecular cancer · 2024Review
- Tertiary lymphoid structures in diseases: immune mechanisms and therapeutic advances.Signal transduction and targeted therapy · 2024Review
- Resident memory T cells and cancer.Immunity · 2024Review
- From mitochondria to tumor suppression: ACAT1's crucial role in gastric cancer.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundCancer stem cells (CSC) define a population of rare malignant cells endowed with 'stemness' properties, such as self-renewing, multipotency and tumorigenicity. They are responsible for tumor initiation and progression, and could be associated with resistance to immunotherapies by negatively regulating antitumor immune response and acquiring molecular features enabling escape from CD8 T-cell immunity. However, the immunological hallmarks of human lung CSC and their potential interactions with resident memory T (T
methodsWe generated a non-small cell lung cancer model, including CSC line and clones, and autologous CD8
resultsUnlike their parental tumor cells, lung CSC are characterized by the initiation of an epithelial-to-mesenchymal transition program defined by upregulation of the SNAIL1 transcription factor and downregulation of phosphorylated-GSK-3β and cell surface E-cadherin. Acquisition of a CSC profile results in partial resistance to T
conclusionOur data support the rational design of immunotherapeutic strategies targeting CSC to optimize their responsiveness to local CD8
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.